Novartis gene therapy approved, but will come at cost of more than $2 million

Share

A gene therapy approved by the FDA offers a potential one-time fix for a rare genetic condition known as spinal muscular atrophy that is fatal to young children.

Novartis’ Zolgensma is only the second gene therapy for an inherited disorder to be cleared for commercial use in the U.S. However, the therapy is also notable for its price. At $2.125M per dose, Zolgensma is the most expensive treatment ever brought to market. Novartis intends for that price to be paid in installments of $425,000 a year for five years.

Read the full article at biopharmadive.com…

Share

Comments are closed.

More in Ashton Tweed Connection, News & Trends
Merck boosts late-phase cancer pipeline with $1.1B Peloton buy

Merck struck a deal to buy Peloton Therapeutics for $1.1B upfront days before the biotech was due to list on...

Close